Latest Hotspot

EBGLYSS® (lebrikizumab) received European Commission approval for treating moderate-to-severe atopic dermatitis

24 November 2023
3 min read

Almirall S.A., an internationally recognised biopharmaceutical firm specialising in medicinal dermatology, has received approval from the EC for the usage of EBGLYSS (lebrikizumab) in the therapy of adult and teenage patients suffering from medium to acute atopic dermatitis, who are suitable for systemic treatment. The firm plans on initial market launch of the product in Germany and anticipates to extend the launch in more European nations during 2024.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Lebrikizumab, a monoclonal antibody, interacts powerfully with IL-13 and purposefully forestalls the development of the IL-13Rα1/IL-4Rα heterodimer complex and subsequent signals, subsequently halting the biological impact of IL-13. This significant cytokine, IL-13, plays a central role in atopic dermatitis, instigating a type-2 inflammatory cycle in the skin, resulting in skin barrier malfunction, itching, skin thickening, and infection.

Lebrikizumab embodies a substantial advancement for patients suffering from moderate-to-extreme AD who have inadequate control with topical therapy, thanks to its exclusive mode of action, established short and long-term efficacy, and safety verified for up to 2 years. Additionally, it offers a monthly maintenance dose for all patients.

Following its approval by the EC, lebrikizumab provides another essential treatment alternative for individuals grappling with moderate-to-severe AD. "This regulatory achievement underscores Almirall’s devotion to evolving innovative therapies that can significantly enrich the lives of people afflicted with skin diseases," affirmed Dr. Volker Koscielny, Almirall's Chief Medical Officer.

Almirall possesses the licensing rights for the development and commercialization of lebrikizumab for various dermatological conditions, including atopic dermatitis, throughout Europe. Eli Lilly and Company retains exclusivity for the product's growth and dissemination in the United States as well as other nations excluding Europe. Further regulatory verdicts for lebrikizumab in moderate-to-severe atopic dermatitis from additional European territories, including the UK and Switzerland, are anticipated by Almirall.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

According to the data provided by the Synapse Database, As of November 23, 2023, there are 25 investigational drugs for the IL13 target, including 36 indications, 46 R&D institutions involved, with related clinical trials reaching 427, and as many as 17846 patents.

Lebrikizumab targets IL-13 and is primarily used in the treatment of dermatitis, atopic eczema, and other related conditions. The drug has reached the highest phase of development globally, indicating its advanced stage of clinical trials and readiness for regulatory approval. In China, Lebrikizumab is in the early stages of development, with an IND application submitted. The drug is regulated under the Fast Track designation, highlighting its potential to address unmet medical needs efficiently.

图形用户界面, 文本, 应用程序

描述已自动生成

What are CDKs inhibitors and how do you quickly get the latest development progress?
What are CDKs inhibitors and how do you quickly get the latest development progress?
24 November 2023
The development of inhibitors around the entire CDK family has become an important branch of drug development in the field of oncology in recent years.
Read →
US approved Truqap (capivasertib) and Faslodex combo for advanced HR-positive breast cancer
Latest Hotspot
3 min read
US approved Truqap (capivasertib) and Faslodex combo for advanced HR-positive breast cancer
24 November 2023
US approval granted for combination of Truqap (capivasertib) and Faslodex for treating advanced HR-positive breast cancer patients.
Read →
An analysis of LY-3537982's R&D progress and its clinical results presented at the 2023 AACR Annual Meeting
An analysis of LY-3537982's R&D progress and its clinical results presented at the 2023 AACR Annual Meeting
24 November 2023
The initial results from LOXO-RAS-20001, a phase 1 study of LY3537982 in patients (pts) with KRAS G12C-mutant advanced solid tumors were reported at the AACR Congress.
Read →
Polaris Group begins phased BLA submission for ADI-PEG 20 to the U.S. FDA for Malignant Pleural Mesothelioma management
Latest Hotspot
3 min read
Polaris Group begins phased BLA submission for ADI-PEG 20 to the U.S. FDA for Malignant Pleural Mesothelioma management
24 November 2023
Polaris Group commences phased submission of a BLA for ADI-PEG 20 to the U.S. FDA to manage Malignant Pleural Mesothelioma.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.